RedHill Biopharma Ltd.
RDHL Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$0.39
KIRA · Stoqly’s AI analyst, in plain words
- RedHill Biopharma Ltd. had only $0.3M of revenue in fiscal 2025: it is still developing what it sells. It spent $2.0M on research and development, 25% of its operating costs.
- Its operating margin was −2,776.9%, down 2,696.4 pts: of every 100 in sales, about −2,777 is left after running the business.
- RedHill Biopharma Ltd. lost $0.4M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$9.7M in fiscal 2025, −3,376.2% of revenue. At that burn of $9.7M a year, its $4.0M of cash and short-term investments would last about 0.4 years.
Market cap
—
P/E
—
Revenue
$0.3M
Net income
−$0.4M
Free cash flow
−$9.7M
Operating margin
−2,776.9%
RedHill Biopharma Ltd. in 30 seconds · fiscal 2025
Are shareholders being diluted?
+156.4%
A lot. The share count rose 156.4% last year, so each share owns noticeably less.
Does it make a profit?
$2.0M R&D
Not yet: it has no meaningful sales. It spent $2.0M on research and development, 25% of its operating costs.
How long would its cash last?
0.4 yrs
Not long. It burns $9.7M a year and holds $4.0M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
1 / 7
It passes 1 of 7 health tests, but most of them need sales, so the score says little before revenue starts.
What RedHill Biopharma Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 27, 2026
- Legal name
- RedHill Biopharma Ltd.
- CIK
- 0001553846
RedHill Biopharma Ltd. · RDHL · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $85.8M | $61.8M | $6.5M | $8.0M | $0.3M |
| Revenue growth | 33.2% | −27.9% | −89.4% | 23.2% | −96.4% |
| Gross margin | 42.4% | 46.1% | 47.0% | 60.3% | — |
| Operating margin | −94.6% | −69.3% | −146.2% | −80.5% | −2,776.9% |
| Net income | −$97.7M | −$71.7M | $23.9M | −$8.3M | −$0.4M |
| Net margin | −114.0% | −116.0% | 366.2% | −102.8% | −150.0% |
| Diluted EPS | −$0.21 | −$0.12 | $0.01 | $0.00 | $0.00 |
| Cash | |||||
| Cash from operations | −$65.0M | −$29.2M | −$35.8M | −$9.4M | −$9.7M |
| Capital expenditure | $0.1M | $0.2M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$65.2M | −$29.4M | −$35.8M | −$9.4M | −$9.7M |
| FCF margin | −76.0% | −47.5% | −548.7% | −116.6% | −3,376.2% |
| Share count change | 27.7% | 32.5% | 320.4% | 375.6% | 156.4% |
| Debt and strength | |||||
| Cash and short-term investments | $29.5M | $20.0M | $5.6M | $4.6M | $4.0M |
| Debt incl. finance leases | $83.6M | $115M | — | — | — |
| Shareholders' equity | $8.9M | −$48.4M | $2.1M | −$4.7M | $4.3M |
| Current ratio | 1.1x | 0.4x | 0.8x | 0.5x | 0.3x |
| Interest coverage | −4.9x | −1.0x | −1.0x | −4.3x | −5.5x |
| Returns and quality | |||||
| Return on capital | −101.7% | −72.2% | — | — | — |
| Return on equity | −859.7% | — | — | — | — |
| Piotroski F-score | 3 | 3 | 4 | 2 | 1 |
| Altman Z'' | −9.3 | −15.6 | −61.4 | −81.3 | −58.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
RedHill Biopharma Ltd. · RDHL · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.39 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001553846). Latest version: stoqly.net/companies/rdhl. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.